Transfusion Medicine — The Science of Safe Blood

 Blood transfusion is one of the most life-saving medical interventions ever developed. Each year, millions of units of blood are transfused worldwide — for trauma, surgery, haematological disorders, obstetric emergencies, and chronic conditions. Yet transfusion is not without risk. Incompatible blood can trigger fatal immune reactions. Infected blood can transmit deadly pathogens. And errors at any step of the transfusion chain can have catastrophic consequences.

This is why transfusion medicine — and the transfusion science laboratory — exists. The blood bank is one of the most high-stakes areas of the medical laboratory, where the science of immunology, haematology, and microbiology converge to ensure that the right blood reaches the right patient safely.

1. Blood Group Systems

1.1 ABO System

The ABO blood group system is the most clinically important for transfusion. It is based on the presence or absence of A and B antigens on the red cell surface, and the corresponding naturally occurring IgM antibodies (anti-A, anti-B) in the plasma:

• Group A: A antigens on red cells; anti-B in plasma

• Group B: B antigens on red cells; anti-A in plasma

• Group AB: A and B antigens; no ABO antibodies (universal recipient)

• Group O: No A or B antigens; anti-A and anti-B in plasma (universal donor for red cells)

ABO antibodies are clinically significant because they are IgM and activate complement, causing acute intravascular haemolysis — the most severe type of transfusion reaction. ABO-incompatible transfusion is a medical emergency with potential mortality. This is why ABO group verification is the cornerstone of pre-transfusion testing.

1.2 Rh System

The Rh system is the second most important blood group system. The D antigen (RhD) is the most immunogenic — individuals who are RhD negative will form anti-D antibodies if exposed to RhD-positive red cells (through transfusion or pregnancy). Anti-D is an IgG antibody that does not fix complement but can cause delayed haemolytic transfusion reactions and, critically, haemolytic disease of the foetus and newborn (HDFN).

Anti-D prophylaxis (anti-D immunoglobulin, Rh(D) immunoglobulin) given to RhD-negative women after sensitising events (delivery, miscarriage, ectopic pregnancy) prevents HDFN in subsequent pregnancies.

1.3 Other Blood Group Systems

Over 40 blood group systems are recognised by the ISBT. Clinically important ones include Kell, Duffy, Kidd, MNS, and Lewis. Antibodies in these systems (alloantibodies, formed after exposure to foreign red cell antigens) can cause delayed haemolytic transfusion reactions and HDFN. The Duffy system is particularly notable in West Africa — the majority of West Africans are Duffy null (Fy(a-b-)), which explains their resistance to Plasmodium vivax malaria.

2. Pre-Transfusion Testing

2.1 Blood Grouping (ABO and RhD)

Blood grouping involves:

• Forward (cell) grouping: Patient red cells are tested with known anti-A and anti-B reagents

• Reverse (serum/plasma) grouping: Patient serum/plasma is tested against known A and B cells

Both groupings must be concordant. Discrepancies (e.g., forward says A but reverse does not show anti-B) must be investigated before transfusion.

2.2 Antibody Screen (Irregular Antibody Screen)

Patient plasma is tested against a panel of reagent red cells expressing all clinically significant antigens. A positive screen indicates the presence of an alloantibody, which must be identified before compatible blood is issued.

2.3 Crossmatch

The crossmatch tests compatibility between donor red cells and recipient plasma/serum. There are three levels:

• Electronic (computer) crossmatch: No physical mixing — the computer verifies ABO compatibility based on two concordant blood group results and a negative antibody screen. Fast and safe for most patients.

• Immediate spin (IS) crossmatch: Patient serum + donor cells incubated briefly and centrifuged. Detects ABO incompatibility.

• Full (antiglobulin) crossmatch: Includes incubation at 37°C and addition of antihuman globulin (AHG). Required when the antibody screen is positive or the patient has a history of alloantibodies.

2.4 Direct Antiglobulin Test (DAT)

The DAT detects immunoglobulin (IgG) and/or complement (C3d) coating the patient's red cells in vivo. It is positive in: AIHA, HDFN, haemolytic transfusion reactions, drug-induced haemolysis.

3. Blood Components

Modern transfusion practice uses blood components rather than whole blood, allowing targeted therapy:

• Red cell concentrate (packed red cells): For symptomatic anaemia. Threshold typically Hb <70 g/L in stable patients (or <80 g/L in cardiac disease or active bleeding).

• Platelets: For thrombocytopenia or platelet dysfunction with bleeding or before invasive procedures. Threshold typically <10 x10^9/L prophylactically; higher if bleeding or procedure.

• Fresh frozen plasma (FFP): For coagulation factor replacement in DIC, liver disease, massive transfusion, or warfarin reversal.

• Cryoprecipitate: Concentrated source of fibrinogen, Factor VIII, vWF, Factor XIII, and fibronectin. Used for hypofibrinogenaemia (<1.5 g/L), haemophilia A (if Factor VIII concentrate not available), and DIC.

• Albumin: For volume expansion in hypoalbuminaemia and liver disease.

4. Transfusion Reactions

4.1 Acute Haemolytic Transfusion Reaction (AHTR)

Usually due to ABO incompatibility — most commonly caused by clerical errors (wrong blood in tube, wrong patient). Symptoms begin within minutes: fever, chills, back and chest pain, haemoglobinuria, hypotension, and shock. The transfusion must be stopped immediately, IV access maintained, and a transfusion reaction investigation initiated (repeat grouping, DAT, check donation labels, urine for haemoglobin).

4.2 Delayed Haemolytic Transfusion Reaction (DHTR)

Occurs 3–14 days post-transfusion due to anamnestic alloantibody response. The antibody (commonly anti-Kidd, anti-Duffy) was below detectable levels at crossmatch but rises after re-exposure. Presents with unexpected fall in haemoglobin, jaundice, fever. DAT becomes positive. Common in sickle cell patients who receive many transfusions.

4.3 Febrile Non-Haemolytic Transfusion Reaction (FNHTR)

The most common reaction. Caused by cytokines from donor white cells or recipient antibodies against donor HLA antigens. Presents with fever and chills without haemolysis. Managed by slowing or stopping transfusion. Leucodepletion of blood products has significantly reduced FNHTR.

4.4 Transfusion-Related Acute Lung Injury (TRALI)

A severe, potentially fatal reaction occurring within 6 hours of transfusion. Caused by donor anti-HLA or anti-HNA antibodies activating recipient neutrophils in the pulmonary vasculature. Presents with acute onset hypoxia, bilateral pulmonary infiltrates, and fever without circulatory overload. Management is supportive.

4.5 Transfusion-Transmitted Infections (TTI)

All donated blood is screened for HIV, Hepatitis B, Hepatitis C, syphilis, and in some settings, malaria. In sub-Saharan Africa, HTLV and Chagas disease screening may also be performed depending on regional epidemiology. Despite screening, residual risk remains (window period). NAT (nucleic acid testing) has greatly reduced the window period for HIV and Hepatitis C.

5. Blood Safety in West Africa

Blood safety remains a significant challenge across much of West Africa. Key issues include limited voluntary non-remunerated blood donation (voluntary donors are safer than family/paid donors), suboptimal cold chain management in low-resource settings, insufficient NAT screening capacity, and high rates of TTI in the donor population. Efforts by organisations like the West African Health Organisation (WAHO) and national blood services (e.g., National Blood Service Ghana) are working to improve the safety and availability of blood. As laboratory scientists, understanding these challenges — and the rigorous testing protocols that mitigate them — is essential.

Conclusion

Blood transfusion is a gift of life — but only when done safely. The blood bank laboratory is the guardian of that safety. From ABO typing to crossmatching to transfusion reaction investigation, the transfusion science team works tirelessly to ensure that every unit of blood reaches the right patient without harm. It is precision medicine in its most literal sense — because getting it wrong can cost a life.